Finding the "killer app" for treating obese individuals has seen no shortage of efforts result in failure over the years. The slow start of VIVUS' (NASDAQ:VVUS) Qsymia has investors doubting the market potential of both it and Arena Pharmaceuticals' (NASDAQ:ARNA) new drugs targeting the problem. In the following video, health care bureau chief Brenton Flynn runs through yet another example of a novel obesity treatment approach that seems destined for failure from EnteroMedics (NASDAQ: ETRM).
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 01/28/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return